Sanara MedTech Inc.

SMTI

US79957L1008

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:47:46 2024-04-25 pm EDT			5-day change	1st Jan Change
31.95 ^USD	-1.69%		-6.00%	-22.21%

Apr. 18	Sanara Medtech Inc. Announces $55 Million Debt Facility	CI
Apr. 05	Sanara MedTech Appoints Jake Waldrop as Chief Operating Officer	MT

Sanara MedTech Inc.(NasdaqCM:SMTI) added to S&P Global BMI Index

September 20, 2021 at 12:00 am EDT

Latest news about Sanara MedTech Inc.

Sanara Medtech Inc. Announces $55 Million Debt Facility	Apr. 18	CI
Sanara MedTech Appoints Jake Waldrop as Chief Operating Officer	Apr. 05	MT
Sanara MedTech Inc. Announces Executive Changes, Effective April 15, 2024	Apr. 05	CI
Cantor Fitzgerald Cuts Price Target on Sanara MedTech to $44 From $49, Maintains Overweight Rating	Mar. 27	MT
Transcript : Sanara MedTech Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
Earnings Flash (SMTI) SANARA MEDTECH Posts Q4 Revenue $17.7M, vs. Street Est of $16.5M	Mar. 25	MT
Sanara MedTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Sanara MedTech Reports Higher Preliminary Q4 Revenue	Feb. 22	MT
Sanara MedTech Inc. Announces Unaudited Preliminary Net Revenue Results for the Fourth Quarter and Full-Year 2023	Feb. 22	CI
Sanara MedTech Secures Exclusive Licensing Deal with Tufts University for 18 Collagen Peptides	Jan. 03	MT
Cantor Fitzgerald Adjusts Price Target on Sanara MedTech to $49 From $59, Maintains Overweight Rating	Nov. 15	MT
Transcript : Sanara MedTech Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Sanara MedTech Q3 Loss Narrows, Revenue Rises; Shares Fall After Hours	Nov. 13	MT
Earnings Flash (SMTI) SANARA MEDTECH Reports Q3 Revenue $16M, vs. Street Est of $18.8M	Nov. 13	MT
Sanara MedTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Sanara MedTech Inc. Announces BIASURGE Advanced Surgical Solution Updates	23-10-10	CI
Transcript : Sanara MedTech Inc., Q2 2023 Earnings Call, Aug 15, 2023	23-08-15
Earnings Flash (SMTI) SANARA MEDTECH Reports Q2 Revenue $15.8M, vs. Street Est of $16.9M	23-08-14	MT
Sanara MedTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Sanara MedTech Acquires Selected Assets Related to Its Collagen Products Business	23-08-02	MT
Sanara MedTech Inc. acquired Certain Assets Related to its Collagen Products Business from Applied Nutritionals, LLC, The Hymed Group Corporation, and Dr. George Petito for 25.3 million.	23-08-01	CI
Sanara MedTech Inc.(NasdaqCM:SMTI) added to Russell 3000E Growth Index	23-06-23	CI
Sanara MedTech Inc.(NasdaqCM:SMTI) added to Russell Small Cap Completeness Index	23-06-23	CI
Sanara MedTech Inc.(NasdaqCM:SMTI) added to Russell 2500 Index	23-06-23	CI
Sanara MedTech Inc.(NasdaqCM:SMTI) added to Russell 3000 Index	23-06-23	CI

Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

32.5 USD

Average target price

44 USD

Spread / Average Target

+35.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANARA MEDTECH INC.	-22.21%	280M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.27%	358B
MERCK & CO., INC.	+19.22%	322B
ABBVIE INC.	+7.71%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-11.69%	149B
AMGEN INC.	-6.30%	146B

Other Pharmaceuticals